VentriPoint Diagnostics (TSE:VPT) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Ventripoint Diagnostics and ASCEND Cardiovascular have signed a term sheet for a non-exclusive license to integrate Ventripoint’s VMS+ technology into ASCEND’s Gen3Echo platform, aiming to enhance cardiovascular diagnostics. This collaboration promises to improve diagnostic accuracy and streamline workflows for echocardiographers by combining cutting-edge AI and machine learning technologies.
For further insights into TSE:VPT stock, check out TipRanks’ Stock Analysis page.
